摘要
目的比较匹伐他汀与阿托伐他汀治疗缺血性脑卒中的临床疗效。方法选取绵阳市中心医院2014年3月—2016年6月收治的缺血性脑卒中患者140例,按照随机数字表法分为匹伐他汀组与阿托伐他汀组,每组70例。匹伐他汀组患者给予匹伐他汀治疗,阿托伐他汀组患者给予阿托伐他汀治疗,两组患者均持续治疗24周。比较两组患者治疗前及治疗后24周低密度脂蛋白胆固醇(LDL-C)、颈动脉内膜中层厚度(IMT)及实验室检查指标。结果治疗前及治疗后24周,两组患者LDL-C及左颈总动脉、右颈总动脉、左颈内动脉、右颈内动脉IMT比较,差异无统计学意义(P>0.05)。治疗前,两组患者血肌酐、尿素氮、白细胞计数、红细胞计数、血小板计数及肌酸激酶比较,差异无统计学意义(P>0.05);治疗后24周,匹伐他汀组患者尿蛋白阳性率低于阿托伐他汀组,血肌酐、尿素氮、白细胞计数、红细胞计数及肌酸激酶低于阿托伐他汀组,血小板计数高于阿托伐他汀组(P<0.05)。结论匹伐他汀与阿托伐他汀治疗缺血性脑卒中患者疗效相当,但匹伐他汀可在一定程度上缓解药物不良反应情况。
Objective To compare the clinical effect of pitavastatin and atorvastatin in the treatment of ischemic stroke. Methods A total of 140 cases of ischemic stroke patients were selected from March 2014 to June 2016 in Mianyang Central Hospital,which were divided into pitavastatin group and atorvastatin group according to random number table method,70 cases in each group. Pitavastatin group was treated with pitavastatin,atorvastatin group was treated with atorvastatin,both groups were treated for 24 weeks. The LDL-C,carotid artery IMT and laboratory related indexes before and after treatment of 24 weeks were compared between the two groups. Results Before and after treatment of 24 weeks,no significantly differences in LDL-C,carotid artery IMT was found between the two groups（ P 〉 0. 05）. Before treatment,no significantly differences in serum creatinine,urea nitrogen,white blood cell count, red blood cell count, blood platelet count or creatine kinase was found between the two groups（ P 〉 0. 05）; after treatment of 24 weeks,pitavastatin group of positive rate of urine protein was lower than atorvastatin group,serum creatinine,urea nitrogen,white blood cell count,red blood cell count and creatine kinase were lower than atorvastatin group,blood platelet count was higher than atorvastatin group（ P 〈 0. 05）. Conclusion Pitavastatin has a same effect in the treatment of ischemic stroke with atorvastatin,but it can relife the adverse reaction in a degree.
出处
《实用心脑肺血管病杂志》
2016年第B12期144-146,共3页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
